BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines

Cancer Immunity

Volumn 10, Issue , 2010, Pages 1-9

  Woloszynska Read, Anna ^a   James, Smitha R ^a   Song, Chajoun ^b   Jin, Boquan ^b   Odunsi, Kunle ^a   Karpf, Adam R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

BORIS; CT antigens; DNA methylation; Gene expression; Human; Ovarian cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLDEOXYCYTIDINE; ADENOVIRUS VECTOR; BROTHER OF THE REGULATOR OF IMPRINTED SITE; CANCER TESTIS ANTIGEN; GENOMIC DNA; LINE 1 PROTEIN; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; PROTEIN XAGE 1; REGULATOR PROTEIN; SMALL INTERFERING RNA; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER CELL; CELL IMMORTALIZATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA METHYLATION; EPITHELIUM CELL; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INDUCTION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC MODEL; HUMAN; HUMAN CELL; OVARY CELL CULTURE; PROMOTER REGION;

EID: 77955687310     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Smpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625. (PMID: 16034368)
2. Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, Müntefering H, Huber C, Sahin U, Türeci O. Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res 2004; 64: 5988-5993. (PMID: 15342378)
3. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007; 104: 12837-12842. (PMID: 17652518)
4. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jager E. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010; 126: 909-918. (PMID: 19728336)
5. Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008; 14: 2740-2748. (PMID: 18451240)
6. De Smet C, Lurquin C, Lethé B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19: 7327-7335. (PMID: 10523621)
7. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994; 54: 1766-1771. (PMID: 7511051)
8. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 2001; 24: 151-161. (PMID: 11265773)
9. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006; 1: 116-120. (PMID: 17786175)
10. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006; 25: 6975-6985. (PMID: 16715135)
11. Link PA, Gangisetty O, James SR, Woloszynska-Read A, Tachibana M, Shinkai Y, Karpf AR. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res 2009; 7: 851-862. (PMID: 19531572)
12. Loriot A, De Plaen E, Boon T, De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 2006; 281: 10118-10126. (PMID: 16497664)
13. Wischnewski F, Friese O, Pantel K, Schwarzenbach H. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res 2007; 5: 749-759. (PMID: 17634428)
14. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006; 4: 339-349. (PMID: 16687489)
15. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncology 2010; 6: 717-732. (PMID: 20465387)
16. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol 2004; 65: 18-27. (PMID: 14722233)
17. Hoffmann MJ, Müller M, Engers R, Schulz WA. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 2006; 72: 1577-1588. (PMID: 16854382)
18. Rousseaux S, Khochbin S. New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators. Epigenomics 2009; 1: 153-161.
19. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005; 65: 7763-7774. (PMID: 16140944)
20. Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 2002; 12: 399-414. (PMID: 12191639)
21. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005; 65: 7751-7762. (PMID: 16140943)
22. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007; 7: 21. URL: http://www.cancerimmunity.org/v7p21/071122.htm
23. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC 3rd, Lobanenkov VV. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 2002; 99: 6806-6811. (PMID: 12011441)
24. Suzuki T, Kosaka-Suzuki N, Pack S, Shin DM, Yoon J, Abdullaev Z, Pugacheva E, Morse HC 3rd, Loukinov D, Lobanenkov V. Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS. Mol Cell Biol 2010; 30: 2473-2484. (PMID: 20231363)
25. Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008; 122: 777-784. (PMID: 17957795)
26. Yawata T, Nakai E, Park KC, Chihara T, Kumazawa A, Toyonaga S, Masahira T, Nakabayashi H, Kaji T, Shimizu K. Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog 2010; 49: 532-544. (PMID: 20082319)
27. Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One 2010; 5: e9738. (PMID: 20305816)
28. Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, Liu C, Chang SS, Ostrow KL, Westra WH, Begum S, Dhara M, Califano J. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 2009; 4: e4961. (PMID: 19305507)
29. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate 2010; in press. (PMID: 20583133)
30. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res 2008; 14: 3283-3290. (PMID: 18519754)
31. Zhou XC, Song CJ, Wang X, Tian Y, Jin BQ. [Preparation of the monoclonal antibodies against human BORIS and the expression pattern of BORIS in normal and diseased human mammary tissues]. [Article in Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007; 23: 353-355. (PMID: 17428394)
32. Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem 2005; 77: 504-510. (PMID: 15649046)
33. De Smet C, Loriot A. DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey. Epigenetics 2010; 5: in press. (PMID: 20305381)
34. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005; 6: 597-610. (PMID: 16136652)
35. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556. (PMID: 11932749)